Point-of-care molecular diagnostics: the federally funded company landscape
Research question: Which companies are building federally funded point-of-care molecular diagnostics, and how do their technical approaches actually differ?
Executive summary
Point-of-care (POC) molecular diagnostics — tests that detect nucleic acids or pathogens at the bedside, in the field, or at home rather than in a central lab — recur throughout federal SBIR/STTR funding. This landscape maps a set of the companies building them and, more usefully, groups them by HOW they do it.
Across SBIR/STTR, a keyword search surfaces 614 POC-molecular award records from 301 candidate companies (1999–2026). Those 301 are keyword matches, not individually reviewed. From them we selected ten companies and reviewed each for technical relevance — spanning five technology and application groups, from single-use isothermal home tests to amplification-free single-molecule detection — checking each against its own website and public reporting rather than relying on grant abstracts alone.
The takeaway: this is not one technology, and a grant is not a product. Approaches differ sharply in sample type, time-to-result, multiplexing, and where the test can physically run; and what a company was funded to research years ago is often not what it sells today. Both distinctions matter more than any funding total.
Five technology and application groups, not one market
Amplification-based test systems: copy the target nucleic acid to detect it — via isothermal chemistry (e.g. Lucira Health's RT-LAMP) or PCR — packaged as portable or automated sample-to-answer systems. Companies here: Lucira Health, AI Biosciences (the µTitan instrument), GoDx (the GoDEVICE platform), and CrossLife Technologies (real-time RT-PCR kits).
Amplification-free / novel-biosensor detection: detect the target without copying it, using nanophotonic biosensors, single-molecule counting, or CMOS bioelectronics. This trades amplification chemistry for novel readout physics. Companies: Nanopath (nanophotonic, urine), Scanogen (single-molecule "SMOLT", blood), Quicksilver Biosciences (CMOS biosensor).
Pathogen ID + antimicrobial susceptibility (AST): goes beyond "is a pathogen present" to "which one, and what will kill it" — directly relevant to antibiotic stewardship. Company: GeneCapture.
Host-response signatures: instead of finding the pathogen, read the patient's own immune gene-expression response to triage infection and sepsis. Company: Inflammatix.
Sample preparation (enabling layer): the unglamorous bottleneck — getting clean nucleic acid out of blood, urine, or swab into the assay. Company: Redbud Labs (microfluidic extraction, the Redbud NA1).
These groups mix three overlapping dimensions — detection chemistry (how the target is found), clinical use (what is tested, and where), and enabling sample preparation — so a company can belong to more than one; we place each by its most distinctive feature. They are not interchangeable: an instrument-free isothermal home test and a single-molecule blood analyzer solve different problems for different settings, which is the useful lens for a diligence shortlist.
The landscape at a glance
| Company | Technical approach | Target / setting (current, unless noted) | Phase II* | Funders |
|---|---|---|---|---|
| Lucira Health | Isothermal (RT-LAMP), single-use | Respiratory home tests (historical) · STI research (funded) · assets acquired by Pfizer 2023 · current availability unverified | 3 | NIH, NSF |
| AI Biosciences | Automated molecular instrument (PCR/isothermal) | Sample-to-answer POC (µTitan) | 1 | NIH |
| GoDx | Integrated molecular platform | Pathogen detection/surveillance (GoDEVICE); funded work: enteric | 2 | NIH |
| CrossLife Technologies | Real-time RT-PCR kits | Infectious disease (dengue, etc.); funded work: HPV DNA test | 5 | NIH, NSF |
| Nanopath | Amplification-free nanophotonic biosensor | cUTI + resistance markers (urine); FDA Breakthrough 2025 | 1 | NSF |
| Scanogen | Amplification-free single-molecule (SMOLT) | Bloodstream infection (blood); FDA Breakthrough 2025; funded work also TB | 2 | NIH |
| Quicksilver Biosciences | CMOS bioelectronic biosensor | Early/stealth; funded work: saliva SARS-CoV-2 | 2 | NIH, NSF |
| GeneCapture | Direct pathogen ID + AST | Infection ID + susceptibility (field/clinic) | 3 | DoD |
| Inflammatix | Host-response gene signature | Sepsis/acute-infection triage (TriVerity, FDA-cleared) | 2 | DoD, NIH |
| Redbud Labs | Microfluidic sample prep (enabler) | Nucleic-acid extraction (Redbud NA1) | 3 | NIH |
*Distinct Phase II awards matching THIS study's keyword search, after collapsing cross-source duplicates (see methodology). A company's profile page counts all of its awards — a broader scope — so its Phase II total may be higher. "Funded work" flags where the historical grant differs from the current offering. Regulatory notes are company statements or press/trade reporting as of Sept 2026; a Breakthrough Device designation is not a clearance or approval.
Read across the "approach" and "current vs funded" columns, not the Phase II count — that count reflects federal engagement and search coverage, not product readiness or quality.
What the records show
NIH dominates POC-molecular funding — 417 of 614 award records and 233 of 301 companies — with DoD (118 records) and NSF (56) as focused secondary funders. DoD money concentrates where the military use-case is sharp: field-deployable pathogen ID + susceptibility (GeneCapture) and host-response triage (Inflammatix, whose earliest award here is a DARPA program).
Among the ten selected examples, the clearest technical split is amplification-based vs amplification-free: amplification-based systems (Lucira, AI Biosciences, GoDx, CrossLife) copy the target nucleic acid to detect it, while the amplification-free group (Nanopath, Scanogen, Quicksilver) aims to detect it directly. We are not claiming which is more common in the full field — only describing these examples.
A distinct cluster targets decisions beyond "pathogen present": GeneCapture couples identification with antibiotic-susceptibility testing, and Inflammatix reads the host immune signature — both aimed at antimicrobial stewardship and sepsis triage rather than simple detection.
Regulatory status is uneven across the roster, and the categories differ. Inflammatix reports FDA clearance for its TriVerity test (a marketing authorization). Nanopath (cUTI) and Scanogen (scano-BSI) hold FDA Breakthrough Device designations (2025) — a designation that expedites review but is NOT a clearance or approval and does not establish clinical performance. Lucira received FDA Emergency Use Authorizations (2020–2023), which permitted marketing during the COVID-19 emergency rather than a full clearance. Others among the ten remain in development or stealth.
A grant is not a current product: several companies now sell something different from the work that put them in this search. CrossLife's funded HPV DNA test is not among its current RT-PCR kits; Scanogen's tuberculosis work preceded its current bloodstream-infection focus; Quicksilver's COVID-saliva project predates its current stealth-stage biosensor platform. Read the awards as R&D history, not a catalog.
These are observations about where federal research money and technical effort sit, and how far each company has since travelled — a map of who worked on what, not a verdict on which technology will win or which company is a good investment.
Lucira Health — isothermal home testing, then acquisition
What the awards funded: an NIH/NSF arc from a 2012 Phase I through Phase II awards in 2016, 2017 and 2020 (the last ~$3.0M) for a "low-cost, instrument-free point-of-care" molecular platform, with abstracts spanning respiratory pathogens and sexually transmitted infections (Chlamydia/Gonorrhea).
Technology and regulatory record: the platform used RT-LAMP (loop-mediated isothermal amplification). Lucira received FDA Emergency Use Authorizations (EUAs) — an at-home COVID-19 self-test (November 2020) and a point-of-care COVID-19/flu test (November 2022). An EUA permits marketing during a declared emergency; it is not a full FDA clearance or approval. (Company announcements; trade reporting, MobiHealthNews.)
Corporate status (independent trade reporting): Lucira Health, Inc. filed for Chapter 11 bankruptcy in February 2023 (MedTech Dive, MobiHealthNews). Pfizer acquired its assets for about $36.4 million through the bankruptcy auction in 2023 (GenomeWeb); trade reporting indicated Pfizer planned to discontinue the standalone Lucira Health business (360Dx). Whether any Lucira-branded test remains marketed under Pfizer is not established by our sources.
Uncertainties & diligence: our data captures the research arc, not IP ownership under Pfizer or whether any product line continues. Diligence: current IP ownership; whether any assay is still sold; single-use device economics; the EUA-timing lesson.
Nanopath — amplification-free nanophotonic detection
What the awards funded: NSF Phase I (2021–22) → Phase II (award #2321834, 2023) for an integrated point-of-care molecular system.
From the company and a company press release (reported via BioSpace, Nov 2025): Nanopath uses a nanophotonic biosensing platform for point-of-care molecular testing focused on women's health (pelvic/gynecologic infections); it received an FDA Breakthrough Device designation for a complicated-UTI assay that identifies pathogens plus antibiotic-resistance markers from urine in ~15 minutes; its stated pipeline includes vaginitis, STIs and HPV. Note: a Breakthrough Device designation expedites FDA review — it is not a clearance or approval and does not establish clinical performance.
Data note: NSF award #2321834 appears two-to-three times in our records (NSF feed + USAspending, with differing phase labels/amounts); we count it as one distinct award. Its later multiplexed-UTI Phase II awards fall outside this study's exact keyword search and appear on the company profile.
Uncertainties & diligence: measured limit-of-detection and time-to-result versus PCR; how multiplex breadth scales; whether the readout needs an instrument at the point of care; the clinical evidence behind the Breakthrough designation.
GeneCapture — pathogen ID with antibiotic-susceptibility testing
What the awards funded: a DoD-heavy portfolio (Chemical/Biological Defense, DTRA, Army, Air Force, Defense Health) from 2016 through 2024, with multiple Phase II awards for a fieldable infectious-disease identification and antibiotic-susceptibility (AST) platform, including wound-pathogen ID.
From the company's website (company statements): GeneCapture's "CAPTURE" technology is described as identifying 200+ pathogens from a raw sample in ~1 hour, adding antibiotic-susceptibility results in ~90 minutes more, for decentralized/field use — consistent with the funded work. No FDA clearance or authorization is stated on the company site.
Uncertainties & diligence: heavy defense funding signals a field/military use-case; the civilian clinical pathway, throughput and regulatory status are not established. Diligence: turnaround versus culture; organism/resistance panel breadth; a clearance strategy for civilian clinical use.
Inflammatix — host-response instead of pathogen detection
What the awards funded: an early DARPA Phase II (2017) on point-of-care host–pathogen monitoring, then NIH awards (2021, 2023) validating and developing blood-based multi-RNA gene-expression signatures for sepsis and acute-infection triage.
From the company's website (company statements): host-response is confirmed as the approach; its lead product TriVerity reports bacterial-infection, viral-infection and severity scores and, per the company, has received FDA clearance — a marketing authorization, distinct from an Emergency Use Authorization or a Breakthrough Device designation. A clinical-validation study was published October 2024. This clearance is the company's own statement; we did not independently confirm it against FDA records.
Uncertainties & diligence: host-response is a different paradigm (reads the patient, not the bug); real-world value depends on prospective performance our data does not contain. Diligence: prospective sensitivity/specificity versus procalcitonin and clinician judgment; time-to-result on the reader; reimbursement path.
Scanogen — amplification-free single-molecule detection
What the awards funded: a sustained NIH Phase II program (2017–2026) for culture- and amplification-free bacterial detection directly from blood, plus single-molecule "tethering" multiplex work and an earlier tuberculosis-detection project.
From the company's website and its press release (Oct 15, 2025): the current product is scano-BSI for bloodstream infection, running on the S1 instrument and using Single-MOLecule Tethering (SMOLT) to identify pathogens directly from whole blood in ~2 hours without culture or amplification. It received an FDA Breakthrough Device designation — a designation that expedites review, not a clearance or approval and not evidence of clinical performance — and is under development, not yet available for diagnostic use. TB was an earlier funded project, not the current focus.
Data note: the long run of similarly-titled Phase II awards reflects sequential/renewal funding plus some cross-source duplication, so we cite the programs (bloodstream infection, TB, multiplex), not a summed award count or dollar total.
Uncertainties & diligence: sensitivity directly from whole blood without culture; time-to-result versus blood-culture + PCR; instrument footprint and cost at the point of care.
Selected companies
Real examples from the dataset. Open a full profile to see award history, funding, patents, and more.
Go deeper on this research
This article is a dated snapshot. Explore the live data yourself — the numbers update as new awards are ingested.
Watchlist tracking and funding alerts are included with Scout and above; saving a search for new-match alerts is a Professional feature.
Free accounts see a preview of results; Scout and above unlock the full landscape. Custom research is a separate inquiry.
Methodology
- Population + reproducible search: SBIR/STTR awards whose title or abstract matches a point-of-care term (point-of-care / point of care, or "POC" as a whole word) AND a molecular-method term (molecular, PCR, nucleic acid, isothermal, amplification, pathogen, CRISPR, sequencing), with award date on/before the 27 September 2026 extraction. Broad terms such as "assay" and "diagnostic" are deliberately excluded (they over-match generic assays); LAMP-based work is captured via "isothermal"/"amplification". One definition is used throughout, and it returns 614 award records across 301 companies (427 Phase I, 187 Phase II, 0 Phase III).
- Source coverage: SBIR.gov, USAspending, NSF and NIH RePORTER award records, as of the extraction date above. Phase is matched exactly (Phase I / Phase II), so Phase III is never counted as a Phase II; this cohort contains no Phase III awards.
- Deduplication: 614 is the count of source RECORDS, and it still includes cross-source duplicates — the same award reported by two feeds (e.g. NSF or NIH RePORTER and USAspending). We did NOT strip those from the 614. Where deduplication IS applied: (a) the table's per-company Phase II counts collapse duplicates matched on company + a normalized award identifier + agency (contract number + amount alone is insufficient, since feeds report different amounts for the same award); and (b) as a sizing estimate, that same method reduces the 614 records to roughly 605 distinct awards (nine collapse, including Nanopath's NSF #2321834). The headline count stays "614 award records"; profiles cite distinct awards.
- Review scope: the 301 companies are keyword matches (candidates), not individually reviewed. The ten featured companies were each reviewed for technical relevance — the classification is read from the award abstracts AND checked against the company's own website (company statements) and, where noted, independent trade reporting or a company press release, as of September 2026. We did not pull FDA.gov records directly; regulatory statements are attributed to the company or the reporting outlet. Where a company's current offering differs from the funded project, both are stated. Nothing is inferred from funding size or agency.
Limitations
- This is a keyword-defined map, not a census: the search will miss companies that describe the same work in different words, and may include adjacent work that uses the terms loosely. It is a starting shortlist, not the complete field.
- The headline "614" counts source records and still contains cross-source duplicates; it is not a distinct-award count. Deduplication is applied only to the table's per-company Phase II counts and to the ~605 sizing estimate (see methodology), and even there some duplicates may remain because feeds report the same award differently.
- A grant is not a current product. Several profiled companies now offer something different from the funded work, and one (Lucira) was acquired by Pfizer in 2023 with its current product availability unverified; we flag current-vs-funded in the table and profiles, but company status can change after our September 2026 checks.
- The 301 companies are keyword-matched candidates, not individually vetted; only the ten featured examples were reviewed for technical relevance. Regulatory notes — FDA clearance, Emergency Use Authorization (EUA), and Breakthrough Device designation are three different things; a Breakthrough designation is neither a clearance nor evidence of performance — are drawn from company statements or trade reporting we cite, and should be verified against official FDA records. Nothing here establishes clinical performance or investment quality.
- No growth or trend claims: comparable year-over-year coverage is not reliable enough here, so we make no funding-trajectory statement. And we draw no conclusions from the absence of a Phase II or of private financing — our records are incomplete on both.
Sources
- Underlying records — SBIR/STTR awards (SBIR.gov) →
- Underlying records — Federal awards (USAspending) →
- Underlying records — NSF award search →
- Company/reporting — Lucira Health / Pfizer acquisition (GenomeWeb reporting) →
- Company/reporting — Nanopath Breakthrough designation (company press release, via BioSpace, 2025) →
- Company/reporting — Scanogen (company site: scano-BSI, SMOLT) →
- Company/reporting — Inflammatix (company site: TriVerity) →
- Company/reporting — GeneCapture (company site: CAPTURE) →
- Explore related companies (broad search — not this study's exact list) →
Attribution
Source: Innovator Lens dataset and analysis, snapshot 27 September 2026. The 301 candidate companies, 614 award records, agency breakdowns, and the technology grouping and findings are Innovator Lens analysis; award figures were calculated from government award records (SBIR.gov, USAspending, NSF, NIH RePORTER) aggregated in Innovator Lens, and those underlying sources are identified in the methodology and linked from each company profile. Company product status, acquisitions, and regulatory statements draw on the separately cited company announcements, official records, and public reporting listed above.
Dated research snapshot. Figures reflect the data as of the 27 September 2026 data extraction — awards dated on or before that date; recent fiscal years are partial, and nothing here implies coverage of awards dated after the extraction. The live product updates as new awards are ingested, so exploring the landscape may show different, more current numbers.